medigraphic.com

2011, Number 3

<< Back Next >>

Cir Cir 2011; 79 (3)

Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease. Three years of experience

Orozco-Gómez LP, Hernández-Salazar L, Moguel-Ancheita S, Ramírez-Moreno MA, Morales-Cruz MV

Language: Spanish
References: 18
Page: 225-232
PDF size: 450.53 Kb.


ABSTRACT

Background: The “Early Treatment for Retinopathy of Prematurity Cooperative” reported a failure rate of 55.2% using laser in zone 1 for treatment of retinopathy of prematurity (ROP). We need to offer better alternatives for those patients. We undertook this study to evaluate the efficacy of combined laser-ranibizumab therapy for ROP with thresholdprethreshold and “plus disease” and to study development of the newborn.
Methods: This is a prospective, experimental, longitudinal and open study including newborns of either ‹32 weeks of gestation or with a birth weight ‹1500 g, with threshold-prethreshold retinopathy or “plus” disease. The effect of treatment was analyzed and development of the newborn was determined.
Results: We studied 34 eyes of 17 patients. Age at birth was 29.9 ± 2.6 weeks. Birth weight was 1,120 ± 253 g. The statistics demonstrated an important relationship between severity of retinopathy and early birth age, along with a high probability of threshold-prethreshold disease at 29.4 weeks of age or 1204 g birth weight. The Bayley scale reported normal development in 23.5% of cases, global retardation in 23.5%, psychomotor retardation but normal mental behavior in 29.4%, and mental retardation but normal psychomotor development in 23.5%. We demonstrated regression of retinopathy in all cases. Persistence of vascular tortuosity was present in 17.6% of cases without vascular dilatation, and vitreous membrane development was demonstrated in 11.7% of patients.
Conclusions: Laser-ranibizumab treatment has allowed a better control of retinopathy for threshold-prethreshold and “plus” disease in this group of patients.


REFERENCES

  1. Roum JH, Bohild R, Mc Elvancy NG. Screening of premature infants for retinopathy of prematurity. Pediatrics 1997;86:1277-1282.

  2. Yannuzzi LA, Guyet DR, Green WR. The Retina Atlas. St. Louis: Mosby; 1996. pp. 470-479.

  3. Todd DJ. Retinopathy of prematurity in infants less than 32 weeks gestation at birth in New South Wales in 1993-1994. Ped Child Health 1999;35:355-357.

  4. Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens: preliminary report. Am J Ophthalmol 1942;25:203-204.

  5. Shih SC, Ju M, Liu N, Smith LE. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest 2003;112:50-57.

  6. Capone A, Díaz-Rohena R. Diode laser photocoagulation for zone 1 threshold retinopathy of prematurity. Am J Ophthalmol 1993;16:444- 450.

  7. Hunter DG, Repka MX. Diode laser photocoagulation for threshold retinopathy of prematurity. Ophthalmology 1993;100:238-244.

  8. Landers MB III, Toth CA. Treatment of retinopathy of prematurity with argon laser photocoagulation. Arch Ophthalmol 1992;110:44-47.

  9. Bakri SV, Snyder MR, Reide JM, Pulido JS, Ezza MK, Singh RJ. Pharmakokinetics of intravitreal ranibizumab (lucentis). Ophthalmology 2007;114:2179-2182.

  10. Allegaert K, Van de Velde M, Casteels I, Naulaers G, Vanhole C, Devlieger H. Cryotherapy for threshold retinopathy: perioperative management in a single center. Am J Perinatol 2003;20:219-226.

  11. Ben-Sira I, Nissenkom I. Long term results of cryotherapy for active stages of retinopathy of prematurity. Ophthalmology 1986;3:1423-1428.

  12. Coats DK, Miller AM, McCreery KM, Holz ER, Paysse EA. Involution of threshold retinopathy of prematurity after diode laser photocoagulation. Ophthalmology 2004;111:1894-1898.

  13. Orozco-Gómez L, Ruiz-Morfín I. Prevalencia de la retinopatía del prematuro. 12 años de detección en el Centro Médico Nacional 20 de Noviembre. Cir Cir 2006;74:3-9.

  14. González-Urquidi J, De la Fuente-Torres MA. Incidencia de la retinopatía del prematuro en el Hospital Dr. Manuel Gea González. Rev Mex Oftalmol 2004;78:1-4.

  15. Sawada O, Kawamura H, Kakinoki M, Ohji M. Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:1379-1381.

  16. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Ophthalmology 2009;148:536-543.

  17. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RS. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859.

  18. Meadow W, Santos J. Reflexiones éticas sobre los cuidados intensivos neonatales. Pediatrics 2009;67:77-79.




2020     |     www.medigraphic.com